From GlobeNewswire: 2025-04-05 07:00:00

Beam Therapeutics presented new data from the Phase 1/2 clinical trial of BEAM-302, showing 91% mean corrected M-AAT at Day 28 in the 60 mg cohort. Mutant Z-AAT decreased by 79% in the same cohort. The fourth cohort evaluating 75 mg of BEAM-302 has been initiated, with updated data expected in the second half of 2025. These findings highlight the potential of BEAM-302 as a precision genetic medicine for alpha-1 antitrypsin deficiency (AATD), a genetic disorder causing early onset emphysema and liver disease. Beam plans to continue the trial and dose the first patient in Part B in the second half of 2025.



Read more at GlobeNewswire: Beam Therapeutics Presents Additional Data for BEAM-302 in